C12Y 305/01028
N-acetylmuramoyl-l-alanine amidase
Official title: N-Acetylmuramoyl-L-alanine amidase (3.5.1.28)
C12Y305/01028 (N-acetylmuramoyl-l-alanine amidase) appears on 16 US grants and 36 published applications in this corpus.
Search patents in C12Y- Granted patents
- 16
- Published applications
- 36
- Assignees
- 24
- Inventors
- 73
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 2 |
| 2013 | 0 | 3 |
| 2014 | 2 | 3 |
| 2015 | 2 | 0 |
| 2016 | 1 | 6 |
| 2017 | 2 | 2 |
| 2018 | 1 | 1 |
| 2019 | 2 | 1 |
| 2020 | 2 | 3 |
| 2021 | 0 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 3 |
| 2024 | 2 | 2 |
| 2025 | 1 | 5 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant lysin and its use in the treatment of Gram-negative bacterial infections16 Jun 2026US 12,655,409 B2Telum Therapeutics S.L.
- Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same13 May 2025US 12,297,470 B2Novozymes A/S
- Targeted antimicrobials and related compositions, methods and systems11 Jun 2024US 12,005,099 B2Lawrence Livermore National Security, LLC
- Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same16 Apr 2024US 11,959,111 B2Novozymes A/S
- Targeted antimicrobials and related compositions, methods and systems23 Jun 2020US 10,688,163 B2Lawrence Livermore National Security, LLC
- Recombinant lysin and its use in the treatment of gram-negative bacterial infections6 Aug 2026US 2026/0226444 A1
- Compositions and methods for the treatment of actinomycetia infections2 Oct 2025US 2025/0302926 A1Endolytix Technology, Inc.
- Staphylococcal protein variants and truncates18 Sep 2025US 2025/0288657 A1Evaxion Biotech A/S
- Mutant rnase e for enhancing recombinant protein expression21 Aug 2025US 2025/0263679 A1
- Polypeptides Having Peptidoglycan Degrading Activity and Polynucleotides Encoding Same7 Aug 2025US 2025/0250556 A1Novozymes A/S
Most cited
By later US patents
- Endolysins active against Staphylococcus bacteria, pharmaceutical compositions, and methods relating thereto3US 9,872,893 B2University of Maryland, College Park · 2018
- Bacteriophage lytic enzymes as alternative antimicrobials2US 8,962,297 B2The United States of America as represented by the Secretary of Agriculture · 2015
- Methods of generating and screening for lytic chimeric polypeptides1US 10,301,607 B2Hypharm GmbH · 2019
- Targeted antimicrobials and related compositions, methods and systems1US 10,688,163 B2Lawrence Livermore National Security, LLC · 2020
- Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin1US 8,790,639 B2The United States of America as represented by the Secretary of Agriculture · 2014